CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D009422: Nervous System Diseases NIH

(Synonyms: Nervous Sys, Nervous Syste, Nervous System Disease, Nervous System Diseases)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug483 COVID-19 swap test PCR Wiki 0.58
drug738 Delivery of iStride™ device gait treatment using telemedicine Wiki 0.58
drug1215 Injection into olfactory cleft Wiki 0.58
drug835 Electronic questionnaire Wiki 0.41

Correlated MeSH Terms (9)


Name (Synonyms) Correlation
D012640 Seizures NIH 0.58
D020233 Gait Disorders, Neurologic NIH 0.58
D061219 Olfactory Nerve Injuries NIH 0.58
D004827 Epilepsy NIH 0.58
D003072 Cognition Disorders NIH 0.41
D060825 Cognitive Dysfunction NIH 0.20
D020521 Stroke NIH 0.18
D000857 Olfaction Disorders NIH 0.17
D004194 Disease NIH 0.10

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0002515 Waddling gait HPO 0.58
HP:0001250 Seizure HPO 0.41
HP:0001268 Mental deterioration HPO 0.20
HP:0001297 Stroke HPO 0.18
HP:0000458 Anosmia HPO 0.17

There are 3 clinical trials

Clinical Trials


1 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms

The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms

NCT04377425 Neurological Diseases or Conditions Stroke, Acute Seizure Disorder Diagnostic Test: COVID-19 swap test PCR
MeSH:Stroke Seizures Epilepsy Cognition Disorders Cognitive Dysfunction Nervous System Diseases
HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke

Primary Outcomes

Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)

Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms

Time: 6 months

Secondary Outcomes

Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients

Measure: Three months cognitive function of COVID-19 positive patients

Time: 3 months

Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)

Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients

Time: 6 months

Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.

Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients

Time: 6 months

Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients

Measure: Anosmia in COVID-19 positive patients

Time: 6 months

Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls

Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection

Time: 24 months

Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis

Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients

Time: 24 months

2 Intranasal Injection of Platelet-rich Plasma Versus Saline for Treatment of Olfactory Dysfunction

This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PrP) in the treatment of olfactory dysfunction. PrP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. We have completed a pilot study here evaluating it's use in olfactory loss which demonstrated safety and also suggested efficacy. Therefore, we aim to assess the ability of PrP to improve olfactory function in patients with decreased sense of smell.

NCT04406584 Olfactory Disorder Olfaction Disorders Olfactory Nerve Injuries Olfactory Nerve Disorder Olfactory Nerve Diseases Procedure: Injection into olfactory cleft
MeSH:Olfaction Disorders Olfactory Nerve Injuries Olfactory Nerve Diseases Disease Nervous System Diseases
HPO:Anosmia

Primary Outcomes

Description: Using Sniffin' Sticks olfactory testing pens to test smell

Measure: Smelling ability

Time: 6 months

3 Treatment of Hemiparetic Gait Impairments Using Telehealth With the Moterum iStride Solution™

The objective of this research is to investigate the feasibility of delivering gait treatment using the Moterum iStride Solution™ to individuals with hemiparetic gait impairments using a telemedicine modality, the Moterum Digital Platform.

NCT04434313 Telemedicine Gait, Hemiplegic Gait Disorders, Neurologic Stroke Orthotic Devices Gait Analysis Device: Delivery of iStride™ device gait treatment using telemedicine
MeSH:Gait Disorders, Neurologic Nervous System Diseases
HPO:Scissor gait Shuffling gait Spastic gait Steppage gait Unsteady gait Waddling gait

Primary Outcomes

Description: The described delivery method includes using remote physical therapist treatment oversight and physical supervision of treatment activities by trained caregivers. Due to the inclusion criteria, patients already have some risk of falls and need for assistance while walking. The caregivers will record assistance levels provided during treatment. Any adverse events will be immediately reported and reviewed. The remote physical therapists will regularly review assistance levels to ensure the participant is requiring an appropriate level of assistance. The feasibility of safely delivering treatment will be assessed by two measures: (a) the daily safety rate, defined as the percentage of days an adverse event occurred out of the total number of treatment days, and (2) assistance required and adverse events experienced for each participant, compared to the group, and compared to our prior research.

Measure: Feasibility of safely implementing the treatment protocol

Time: Determined at the end of the 12-session treatment period (approximately 4 weeks after beginning the treatment).

Description: The achievability of this treatment delivery method will be assessed by measuring participant compliance to the protocol tasks. These tasks include scheduled treatment sessions, functional and psychosocial outcome measures, and sensor-based activities. Achievability will be defined as the percentage of completed protocol activities out of the total scheduled activities.

Measure: Achievability of telemedicine delivery protocol

Time: Determined within one week after the final follow-up assessment (12-month follow-up) is completed. The 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.

Secondary Outcomes

Description: To enroll patients via telemedicine, the eligibility criteria will be assessed with an additional video gait review performed by physical therapists. The feasibility of screening patients at a distance will be assessed by measuring screening performance, defined as the percentage of enrolled subjects who are removed from the study after later being deemed ineligible (for example, gait is not asymmetric or hemiparetic but appeared so on video, or patient cannot walk independently, etc.) out of all enrolled subjects.

Measure: Feasibility of screening criteria

Time: Determined at the end of the 12-session treatment period (approximately 4 weeks after beginning the treatment).

Description: Participant and caregiver feedback will be necessary to determine preferences and sentiments regarding the delivery method including technology management, training procedures, protocol activities, adequacy of caregiver and therapist support, device benefit, and overall satisfaction with procedures. Feedback will be gathered through a questionnaire using five-point Likert scales and open-ended questions. Questionnaires will be provided after completion of outcome measures at the final, 12-month follow-up assessment. Acceptability will be determined through percentage of positive responses out of the total questionnaire items.

Measure: Stakeholder Acceptability

Time: Determined within one week after the final follow-up assessment (12-month follow-up) is completed. The 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.


HPO Nodes